Please complete all 2 questions below and click 'Submit'. You must answer a minimum of 2 questions correctly to earn a CE certificate.
a. Only patients who are under age 75 years should be considered for transplant
b. Only patients who can receive intensive induction therapy can go on to receive transplant
c. Patients aged 60 years and older with good performance status and no/low comorbidity burden should be considered for transplant
d. Transplant can only be considered after first remission; second remission does not qualify a patient for transplant
a. CPX-351
b. Decitabine
c. Midostaurin
d. Gilteritinib

 

 

Release Date: August 23, 2021
Expiration Date: August 23, 2022

Expected time to complete this activity as designed: 15 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

In this activity, Dr. James M. Foran discusses new concepts in bridging therapy and stem cell transplant in older AML patients. He reviews the safety and efficacy data regarding stem cell transplant in this patient population and explores a number of agents and therapeutic strategies that have been evaluated for bridging to transplant in older AML patients, including midostaurin, CPX-351, decitabine, venetoclax-based regimens, gilteritinib, and the investigational agent Iomab-B.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurse practitioners, pharmacists and other allied healthcare professionals who provide care to patients with acute myeloid leukemia.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Understand the barriers that prevent many older adults with AML from undergoing bridging therapy and allogeneic stem cell transplant
  • Review agents and therapeutic approaches that have been found to be successful in bridging older AML patients to transplant
  • Evaluate and select older patients who would make good candidates for bridging therapy and transplant

Agenda

Bridging to Transplant in Older AML Patients: Old Notions and New Evidence – James M. Foran, MD

Instructions for Participation and Credit

This activity is eligible for credit through August 23, 2022. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

James M. Foran, MD
Associate Professor of Oncology
Mayo Clinic College of Medicine and Science
Jacksonville, Florida

Dr. James Foran received his medical degree from the University of Manitoba Medical School. He continued post-graduate studies as an intern/resident at Beth Israel Hospital; chief medical resident at the Boston VA Medical Center; medical oncology fellow at Dana-Farber Cancer Institute; clinical research fellow at Imperial Cancer Research Fund; and bone marrow transplant fellow at the Royal London School of Medicine. Dr. Foran is currently an Associate Professor of Oncology at Mayo Clinic College of Medicine and Science. In addition, he is a Consultant in both the Division of Hematology/Oncology, Department of Internal Medicine, and the Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Jacksonville, Florida.

Dr. Foran is American Board of Internal Medicine (ABIM) certified in internal medicine and medical oncology, with a certificate of completion of specialist training-UK in medical oncology and Royal College of Physicians of Canada FRCPC (Internal Medicine). He is a member of the Eastern Cooperative Oncology Group and Leukemia and Lymphoma Society. In addition, Dr. Foran is on the editorial board at Clinical Lymphoma and Myeloma, and a reviewer with Annals of Oncology, Biology of Blood and Marrow Transplantation, Blood, Cancer, Journal of Clinical Oncology, and Leukemia and Lymphoma, among others. His major focus is on early phase and investigator-initiated clinical trials in acute leukemia, myelodysplastic syndrome and malignant lymphoma, with collaboration with laboratory-based investigators.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at cmettille@medicaled.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb, Genentech, Helsinn Healthcare SA, and Jazz Pharmaceuticals.

©2021 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 • Newtown, PA 18940, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

MediCom CME CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-21-034-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. James Foran has received honoraria as a consultant for Revolution Medicines, Inc. and honoraria related to formal advisory activities from Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc. and SERVIER. His institution has received grant support related to research activities from AbbVie Inc., Actinium Pharmaceuticals, Inc., Aprea Therapeutics, Aptose Biosciences, Boehringer Ingelheim GmbH, H3 Biomedicine Inc., Kura Oncology, Inc., Takeda Oncology, Trillium Therapeutics Inc., and Xencor.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Lillian McVey, Medical Writer, and Andrea Mathis, Project Manager, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.